Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03388372 |
Recruitment Status :
Completed
First Posted : January 3, 2018
Last Update Posted : January 3, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Glioblastoma | Biological: Nimotuzumab Drug: Temozolomide Radiation: Radiotherapy | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 39 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Efficacy and Safety of Nimotuzumab in Addition to Radiotherapy and Temozolomide for Cerebral Glioblastoma |
Actual Study Start Date : | August 18, 2010 |
Actual Primary Completion Date : | March 23, 2017 |
Actual Study Completion Date : | March 23, 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: Nimotuzumab plus RT and temozolomide.
Nimotuzumab, administered once a week intravenously in addition to radiotherapy with concomitant and adjuvant temozolomide (TMZ) after surgery.
|
Biological: Nimotuzumab
Nimotuzumab, 200 mg as 1-hour intravenous infusion once weekly, from first week to last week of RT for a total of 6 times. Drug: Temozolomide Temozolomide, 75 mg/m2/d was administered orally from the first to the last day of RT. After 4-week break, individualized adjuvant TMZ was given based on MGMT status. The standard 5-day schedule every 4 weeks for six cycles was given for patients with negative MGMT expression. Dose was 150mg/m2 for the first cycle and 200 mg/m2 from the second cycle. The 7-day on/7-day off schedule every 2 weeks for 12 cycles was given for patients with positive MGMT expression. The dose was 100 mg/m2 for the first two cycles and 150 mg/m2 starting from the third cycle. Radiation: Radiotherapy Fractionated 3D conformal RT was given at 2.0Gy per fraction, 5 daily fractions per week for 6 weeks. |
- Progression-free survival (PFS) [ Time Frame: 2 years ]PFS will be calculated as the time from surgery to the date of progression-free.
- Overall survival (OS) [ Time Frame: 2 years ]OS will be calculated as the time from surgery to the date of death.
- Objective Response Rate (ORR) [ Time Frame: 6 months ]ORR: overall response rate (ORR), subjects will be classified according to the RANO criteria, which is a composite of MRI changes, clinical response and changes in steroid use.
- Incidence of adverse events [ Time Frame: 6 months ]Incidence of adverse events.Toxicities will be tabulated and graded according to the NCI Common Toxicity Criteria (CTCAE) version 3.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Newly diagnosed, histologically proven single supratentorial GBM (WHO grade 4);
- EGFR positive;
- >50% of the gross tumor volume removed by surgery;
- Karnofsky performance score (KPS) ≥ 60;
- Adequate renal function (creatinine ≤1.5×upper limit of normal [ULN] or creatinine clearance ≥ 60 mL/min), hepatic function (total bilirubin ≤1.5×ULN and serum transaminases ≤3×ULN), and hematologic function (white blood cell count ≥ 3,000/uL or absolute neutrophil count ≥ 1,500/uL, platelets ≥ 100,000/uL, and hemoglobin ≥ 10 g/dL).
- Tumor tissue was required for central pathology review and re-checking EGFR and MGMT expression status;
- An interval of 2 to 6 weeks between surgery and RT was required.
Exclusion Criteria:
- Negative EGFR expression;
- Prior chemotherapy, anti-EGFR therapy, RT, or a history of malignancy in the previous 5 years;
- Patients with severe complications or active infection;
- Continuous vomiting that could interfere with the oral administration of TMZ;
- Pregnancy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03388372
China, Guangdong | |
Sun Yat-sen University Cancer Center | |
Guangzhou, Guangdong, China, 510060 | |
China | |
Guangdong Brain Hospital | |
Guangdong, China | |
The First Affiliated Hospital/School of Clinical Medicine of Guangdong | |
Guangdong, China | |
The First Affiliated Hospital of Guangzhou Medical University | |
Guangzhou, China | |
Shenzhen People's Hospital | |
Shenzhen, China |
Principal Investigator: | Shao-Xiong Wu, Professor | Sun Yat-sen University |
Responsible Party: | Shao Xiong Wu, Professor, Sun Yat-sen University |
ClinicalTrials.gov Identifier: | NCT03388372 |
Other Study ID Numbers: |
NimotuzumabGBM2010 |
First Posted: | January 3, 2018 Key Record Dates |
Last Update Posted: | January 3, 2018 |
Last Verified: | December 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
glioma phase 2 nimotozumab temozolomide radiotherapy |
Glioblastoma Astrocytoma Glioma Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Glandular and Epithelial |
Neoplasms, Nerve Tissue Temozolomide Nimotuzumab Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Antineoplastic Agents, Immunological |